Retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability

Fabiana Picconi 1,2 • Mariacristina Parravano 3 • Dorina Ylli 1,2 • Patrizio Pasqualetti 4 • Sara Coluzzi 1,2 • Ilaria Giordani 1,2 • Ilaria Malandrucco 1,2 • Davide Lauro 1 • Fabio Scarinci 3 • Paola Giorno 3 • Monica Varano 3 • Simona Frontoni 1,2

Received: 8 December 2016 / Accepted: 30 January 2017 / Published online: 25 February 2017 © The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract

Aims Recent studies have identified neuroretinal abnormalities in persons affected by diabetes mellitus, before the onset of microvascular alterations. However, the role of glycemic variability (GV) on early retinal neurodegeneration is still not clarified.

Methods To explore the relationship between glycemic control and neuroretinal characteristics, 37 persons with Type 1 diabetes mellitus (Type 1 DM) divided into two groups with no signs (noRD) and with mild non-proliferative diabetic retinopathy (NPDR) compared to 13 healthy control participants (C) were recruited. All persons underwent an optical coherence tomography with automatic segmentation of all neuroretinal layers. Measurements of mean of nasal (N)/temporal (T)/superior (S)/inferior (I) macular quadrants for individual layer were also calculated. Metabolic control was evaluated by glycated hemoglobin (HbA1c), and indexes of GV were calculated from continuous glucose monitoring.

Results The difference among the three groups in terms of RNFL thickness was significantly dependent on quadrant (F(6;132) = 2.315; p = 0.037). This interaction was due to a specific difference in RNFL-N thickness, where both Type 1 DM groups showed a similar reduction versus C (−3.9 for noDR and −4.9 for NPDR), without any relevant difference between them (−1.0). Inner nuclear layer (INL) was increased in all quadrants in the two Type 1 DM groups compared to C (mean difference = 7.73; 95% CI: 0.32–15.14, p = 0.043; mean difference = 7.74; 95% CI: 0.33–15.15, p = 0.043, respectively). A negative correlation between RNFL-N and low blood glucose index (r = −0.382, p = 0.034) and positive correlation between INL and continuous overall net glycemic action (−4h) (r = −0.40, p = 0.031; r = −0.39, p = 0.031; r = −0.41, p = 0.021, respectively) were observed in Type 1 DM patients. The triglycerides were positively and significantly correlated to INL (r = 0.48, p = 0.011), in Type 1 DM subjects. GV and triglycerides resulted both independent predictors of increased INL thickness. No correlation was found with HbA1c.

Conclusions Early structural damage of neuroretina in persons with Type 1 DM patients is related to glucose fluctuations. GV should be addressed, even in the presence of a good metabolic control.

Keywords Retinal neurodegeneration • Glycemic variability • Type 1 diabetes mellitus

Introduction

As the worldwide prevalence of diabetes mellitus continues to raise, diabetic retinopathy represents a leading cause of vision loss in many developed countries [1]. The number of people at risk of developing vision loss from diabetes is predicted to double over the next 30 years [2], so it is crucial to develop better means to prevent, identify and treat retinopathy in its earliest stages.
In a recent review, Cheung et al. [3] included exposure to persistent hyperglycemia, longstanding diabetes, altered blood pressure control and certain ethnic origins among the well-established risk factors for DR. Moreover, a single-nucleotide polymorphism Rs2910164 was significantly associated with DR in patients affected by Type 1 and Type 2 diabetes mellitus (Type 1 DM; Type 2 DM) [4]. In Asian populations, BMI levels were inversely associated with DR [5], which may be due to better β cell function in overweight patients [6].

Hyperglycemia instigates the cascade of events that finally leads to development of diabetic retinopathy. However, the role of glycemic control, expressed as HbA1c, on the development of RD is still not fully clarified. Recently, daily glycemic variability (GV) has been proposed as a major contributor to the development of diabetes macrovascular and cerebrovascular complications [7–11]. However, the association between GV and diabetes microvascular complications has yielded inconsistent findings. Recent evidence has emphasized the role of neuroretina in the interactions between neural alterations and microvascular abnormalities [12], and the relationship between GV and retinal neurodegeneration, in the early stages of RD, has been only very recently investigated [13].

The purpose of the present study was to investigate the relative impact of overall glycemic load and of GV on structural changes of neurosensory retina, in persons with Type 1 DM, with no signs (noDR) or mild non-proliferative diabetic retinopathy (NPDR) and without microvascular complications, i.e., absence of peripheral neuropathy and microalbuminuria.

Methods

From the Unit of Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli Hospital of Rome, we recruited 37 patients with Type 1 DM, divided into two groups: noRD group (19 patients) and NPDR group (18 patients). Thirteen healthy participants, without history of ocular disease, no family history of glaucoma or any relevant systemic disease, were enrolled as control group (C), from the medical staff of Department of Ophthalmology, G.B. Bietti Eye Foundation-IRCCS, Rome.

Inclusion criteria for the Type 1 DM patients were: (1) documented diagnosis of Type 1 DM, according to ADA criteria [14]; (2) age between 18 and 75 years; (3) treated with continuous subcutaneous insulin infusion or with multiple daily insulin injections; (4) no signs of retinal vasculopathy or NPDR. Exclusion criteria were: (1) symptomatic diabetic polyneuropathy affecting the lower extremities with positive sensory symptoms such as pain, burning, paresthesia or pricking; (2) abnormal amplitude latency or conduction velocity in motor nerve (either tibial or deep peroneal) and/or in the sural nerve; (3) a Michigan Diabetes Neuropathy Instruments [15] equal to or greater than 2 points; (4) microalbuminuria (urinary albumin/creatinine ratio >30 mg/g); (5) spherical refractive error ≥±6 diopters, astigmatism (cyl) ≥±3 diopters, active or past retinal pathologies, diagnosis of glaucoma or ocular hypertension, opacities of optical media that could influence functional and structural retinal testing; (6) history of ocular surgery. Informed consent was obtained from all individual participants included in the study.

Study design

All subjects underwent a general medical examination and anthropometric parameters. After an overnight fast, blood and urine samples were obtained for the determination of laboratory measurements. Each person underwent a complete ophthalmic examination, with determination of best corrected visual acuity, anterior segment examination, spectral domain optical coherence tomography (SD-OCT) and fundus photography. All Type 1 DM persons were subjected to 72-h continuous glucose monitoring (CGM).

Ophthalmic Assessment

Color stereoscopic fundus photographs were taken after an adequate dilatation by a trained photographer (TRC-50×; Topcon Instrument Corp., Tokyo, Japan). Diabetic retinopathy was graded as noDR and as NPDR by two independent graders experienced in grading DR (MP, FS).

OCT-SD scanning was performed using Heidelberg Spectralis version 1.9.10.0 (Heidelberg Engineering, Heidelberg Germany) with the IR and OCT30 degrees ART examination procedure. A standard imaging protocol used consisted of 20° × 20° volume scans of the macula area with 49 B-scans, with a mean of 16 automatic real-time images (ART) per scan in high-resolution mode. Clinical study-certified investigators performed all images.

Macular measurements were performed using the inbuilt Spectralis mapping software, Heidelberg Eye Explorer (version 6.0c). The Spectralis segmentation software [16] was used to obtain individual retinal layer thickness measurements including: overall retinal thickness (RT), retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), retinal pigment epithelium (RPE), inner retinal layer (IRL) and photoreceptor layer (PR) thickness. The Spectralis mapping software generates automated measures of retinal thickness based on analyses of the central and inner 1000, 3000 and 6000 microns subfield as defined by the Early Treatment Diabetic Retinopathy Study [17]. Measurements of mean of
Assessment of GV indexes

After an overnight fast, the Type 1 DM group underwent 72-h CGM with the Ipro2 System (Medtronic, Northridge, CA), and a subcutaneous sensor (Enlite; Medtronic, Northridge, CA) for CGM was applied on the same day of SD-OCT analysis. From CGM data, the following indexes of GV were calculated [18]: standard deviation (SD); mean amplitude of glucose excursion (MAGE); J-index; mean absolute glucose (MAG); continuous overall net glycemic action (CONGA-1, -2 and -4); low blood glucose (LBGI) and high blood glucose index (HBGI); M value.

Laboratory measurements

Plasma glucose concentrations were measured by the hexokinase method (Modular P Analyzer; Roche). The intra-assay coefficients of variation (CV) were 1.1% and inter-assay CV was 1.9%. The sensitivity of the method was 2 mg/dL (0.11 mmol/L). HbA1c was analyzed by high-performance liquid chromatography (VARIANT 2; BioRad Laboratories, Munich, Germany), with intra- and inter-assay CV of 0.46–0.77 and 0.69–0.91%, respectively.

Plasma total cholesterol, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein cholesterol (LDL) cholesterol were analyzed with a colorimetric enzymatic method (CHOD-PAP; Roche Diagnostics). The intra-assay CV was 1%, and the inter-assay CV was 2.7%. The sensitivity of the method was 0.08 mmol/L. Plasma triglycerides were analyzed with a colorimetric enzymatic method (GPO-PAP; Roche Diagnostics). The intra-assay CV was 1.5%, and the inter-assay CV was 2.4%. The sensitivity of the method was 0.05 mmol/L.

Urinary albumin was determined by the Tina-quant immunoturbidimetric assay (Cobas; Roche Diagnostic, Indianapolis, IN) and urinary creatinine by enzymatic colorimetric test (Beckmann Coulter, California, USA). C underwent an oral glucose tolerance test, to exclude diabetes and impaired glucose tolerance.

Statistical analysis

Differences among noDR, NPDR and C groups were assessed by means of general linear model, taking into account the eventual variance heterogeneity. A measure (eta-squared) of the standardized effect size (SES) was provided allowing to check whether the absence of statistically significant effects could be attributed to the small samples size.

Correlations among interval variables were measured through Pearson’s index, after appropriate log-transformation when necessary. In order to evaluate the adjusted effects of multiple variables on retinal thickness layers, multivariable regression analysis was applied.

Results

Clinical and laboratory characteristics of noDR and NPDR groups of diabetic patients and of C group are reported in Table 1. The three groups were not different, except for age, body mass index (BMI), fasting glucose and HDL chol. C group was younger than NPDR, had lower BMI than NPDR and, as expected, lower plasma glucose concentration than both Type 1 DM groups. The two groups of diabetic patients were comparable for sex, HbA1c, anthropometric characteristics and blood pressure values. However, age and diabetes duration were significantly higher in NPDR, as expected, and HDL chol significantly lower in the NPDR subgroup.

The difference among the three groups in terms of RNFL thickness was significantly dependent on quadrant \((F(6;132) = 2.315; p = 0.037)\). This interaction was due to a specific difference in RNFL-N thickness, where both DM1 groups showed a similar reduction versus C (\(-3.9\) for noDR and \(-4.9\) for NPDR), without any relevant difference between them (\(-1.0\)).

The lack of a significant interaction “Group X Sector” \((F(3.4;75.1) = 1.112; p = 0.358)\) for INL thickness allows to consider a global measure of INL (INL-G), defined as the average value of the INL thickness of the four quadrants. Such value was significantly different in the three groups \((F(2,44) = 3.468; p = 0.039)\), due to larger thickness in noDR group versus C (mean difference = 7.73; 95% CI: 0.32–15.14; \(p = 0.043\)), as well as in NPDR group versus C (mean difference = 7.74; 95% CI: 0.33–15.15; \(p = 0.043\)). On the other hand, INL-G thickness was very similar in the noDR and NPDR groups (\(p = 0.997\); Fig. 1).

Since age, BMI and HDL chol were significantly different among the three groups, we added these variables as covariates in the previous analyses and the patterns remained stable.

Finally, the percentage of patients with both increase in INL-G thickness and decrease in RNFL-N thickness versus the average values of C group is 53% for noDR group and 28% for NPDR group.

Correlation analysis

We did not observe significant correlation between HbA1c and retinal macular layers thickness (consistently, \(p > 0.2\)). In Type 1 DM patients, a negative correlation was observed between LBDM and RNFL-N quadrant \(r = -0.382,\)
Table 1  Clinical and laboratory characteristics of the diabetic group noDR and NPDR compared to C group, mean (SD)

|                     | C        | NoDR     | NPDR     | Test  |
|---------------------|----------|----------|----------|-------|
|                     | n = 13   | n = 19   | n = 18   | degrees of freedom |
| Gender (M/W)        | 5/8      | 9/10     | 10/8     | $\chi^2 = 0.889$ |
|                     |          |          |          | df = 2  |
|                     |          |          |          | $p = 0.641$ |
| Age (years)         | 35.8 (6.1) | 38.2 (10.9) | 44.9 (9.1)$^{bc}$ | $F = -3.934$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p = 0.027$ |
|                     |          |          |          | $\eta^2 = 0.15$ |
| Diabetes duration (years) | –         | 15.8 (10.4) | 22.4 (10.3)$^c$ | $t = -2.269^p$ |
|                     |          |          |          | df = 35  |
|                     |          |          |          | $p = 0.030$ |
|                     |          |          |          | $\eta^2 = 0.13$ |
| BMI (kg/m$^2$)      | 22.6 (2.0) | 24.4 (3.6) | 25.7 (3.1)$^b$ | $F = -3.606$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p = 0.035$ |
|                     |          |          |          | $\eta^2 = 0.14$ |
| Glycemia (mmol/L)   | 4.8 (0.6) | 8.2 (1.6)$^b$ | 8.8 (2.0)$^b$ | $F = -28.008$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p < 0.001$ |
|                     |          |          |          | $\eta^2 = 0.55$ |
| HbA1c (%; mmol/mol) | –        | 7.77 (1.01) | 8.08 (1.11) | $t = -0.283$ |
|                     |          | 61.33 (11.07) | 64.79 (12.17) | df = 36  |
|                     |          |          |          | $p = 0.779$ |
|                     |          |          |          | $\eta^2 = 0.02$ |
| Tot chol (mmol/L)   | 4.0 (0.6) | 4.5 (1.1) | 4.6(1.3) | $F = -1.075$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p = 0.350$ |
|                     |          |          |          | $\eta^2 = 0.04$ |
| HDL chol (mmol/L)   | 1.7 (0.1) | 1.8 (0.3) | 1.5 (0.3)$^c$ | $F = -6.012$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p = 0.005$ |
|                     |          |          |          | $\eta^2 = 0.20$ |
| LDL chol (mmol/L)   | 2.0 (0.6) | 2.4 (0.9) | 2.6 (1.0) | $F = -1.609$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p = 0.211$ |
|                     |          |          |          | $\eta^2 = 0.06$ |
| Trigl (mmol/L)      | 0.8 (0.1) | 0.8 (0.3) | 1.0 (0.5) | $F = -1.853$ |
|                     |          |          |          | df = 2.47  |
|                     |          |          |          | $p = 0.168$ |
|                     |          |          |          | $\eta^2 = 0.07$ |
| Microalb/creat (mg/g) | –     | 7.1 (6.3) | 5.8 (2.7) | $t = -0.421^a$ |
|                     |          |          |          | df = 15.4  |
|                     |          |          |          | $p = 0.679$ |
|                     |          |          |          | $\eta^2 = 0.01$ |
| SBP (mmHg)          | –        | 122.4 (18.5) | 122.2 (31.5) | $t = 0.018$ |
|                     |          |          |          | df = 36  |
|                     |          |          |          | $p = 0.986$ |
|                     |          |          |          | $\eta^2 < 0.01$ |
A positive correlation was observed between CONGA-1, -2, and -4 and INL-G ($r = 0.40$, $p = 0.025$; $r = 0.39$, $p = 0.031$; $r = 0.41$, $p = 0.021$, respectively; Fig. 2). In Type 1 DM patients, triglycerides were positively and significantly correlated to INL-G ($r = 0.48$, $p = 0.011$). Such correlation indexes were not significantly different in noDR and NPDR groups (consistently, $p > 0.20$).

### Multi-variable analysis

Because our data showed a significant effect of CONGA-1, -2, -4 and triglycerides on INL-G thickness, we assessed their effects through multivariable regression analysis. Gv and triglycerides resulted both independent predictors of increased INL-G thickness. More precisely, 39% of INL variance resulted accounted for triglycerides (21%) and Gv (18%); Triglycerides: slope 12.127; standard error 3.654; $t = 3.319$; $p$ value 0.003; cumulative $R^2 = 0.21$; CONGA-2 slope 2.892; standard error 1.005; $t = 2.878$; $p$-value 0.008; cumulative $R^2 = 0.39$.

---

**Table 1 continued**

| Test | degrees of freedom | $p$ value |
|------|--------------------|-----------|
| DBP (mmHg) | – | 74.6 (7.7) | 75.5 (6.7) | 0.670 |
| $df$ = 24.1 | $p = 0.510$ | $\eta^2 = 0.03$ |

$M$ men, $W$ women, $BMI$ body mass index, $HbA1c$ hemoglobin glycated, $Tot$ chol total cholesterol, $HDL$ chol high-density lipoprotein cholesterol, $LDL$ chol low-density lipoprotein cholesterol, $Trig$ triglycerides, $Microalb/creat$ microalbuminuria/creatininuria, $SBP$ systolic blood pressure, $DBP$ diastolic blood pressure. $^a$ $t$-test applied after log-transformation. Statistical significance $^b p < 0.05$ versus C; $^c p < 0.05$ versus noDR.
Discussion

In our study, we observed an increased thickness of INL in persons with no DR and NPDR, compared to healthy groups. Our findings are in agreement with Vujosevic et al. [19] and more recently with Scarinci et al. [20]. Moreover, Bandello F et al. [21] reported that the increase in retinal thickness occurring in macular edema was predominantly located in the INL and extended to neighboring retinal layers in Type 2 DM patients. On the other hand, it has been recently showed a modest and selective reduction in the inner region of the INL in the temporal quadrant in Type 1 DM persons with no or mild RD [13], as well as in the pericentral area of macula in patients with minimal DR [22]. The subtle differences in the macular thickness described in these studies may be explained by the fact that the progressive phenomenon of retinal neurodegeneration was “photographed” in slightly different time phases, but with significantly different findings. In particular, INL includes mainly the nuclei of bipolar and Müller cells and the increase observed in this specific layer may represent a clinical sign of Müller cell activation [19]. Some recent studies have reported that Müller cells respond much earlier to high glucose conditions, than retinal vasculature [23]. Reactive gliosis represents the response of Müller cells to hyperglycemia [24], a process characterized by a specific pathophysiological mechanism: hypertrophy, cellular proliferation, and increased intermediate filament proteins nestin, vimentin and glial fibrillary acidic protein (GFAP) [25]. Increased levels of GFAP have been reported within 6–8 weeks of diabetes induction in animal models [26, 27]. Moreover, a recent study demonstrated that early Müller glial activation seems not to contribute to neurodegeneration, but might indeed have a neuroprotective activity against high glucose-induced neurotoxicity [28]. Therefore, reactive Müller cells are, at the beginning, neuroprotective, but consequently may stop supporting the neurons and contribute to neuronal degeneration [29].

On the other hand, the hypothesis of a vascular alteration to the basis of the increase in INL cannot be excluded.

Some studies [21, 30] showed in the early stages of subclinical macular edema, an increased retinal thickness, which mainly occurs at INL level, likely related to the pathological alteration of the deep capillary plexus and extracellular accumulation of fluid. The inner retina is provided mainly by the inner retina vasculature, which includes the superficial, intermediate and deep capillary plexus. Amacrine and horizontal cells have a specific connection with the intermediate and deep capillary plexus and at the same time interact with the Müller cells within INL. In the light of this particular anatomical structure of the inner retina, it is possible to speculate that the Müller cells have a crucial role in mediating relationship between retinal vessels and neurons [31–33] and, therefore, in the alteration of neurovascular unit that may occur in the early changes of DR, at the level of INL [20].

However, our observation of a significant increase in the INL thickness already in diabetic patients without RD compared to controls allows to hypothesize that the activation of Müller cells could represent the “primum movens” of the retinal neurodegeneration process.

In this study, we also observed a weakly decrease in RNFL thickness in the nasal quadrant of the macular area of diabetic eyes even no sign of DR or with very mild clinical signs of vascular retinopathy. Reduced RNFL thickness may be explained by progressive ganglion cells and astrocytes loss [19]. Different authors have reported a macular thinning of neuroretina suggesting that retinal neurodegeneration is an early event in diabetes mellitus, representing a preclinical stage of DR [34]. van Dijk et al. [22, 35] observed thinning of the total retina caused by a selective GCL thinning in the macular pericentral area and corresponding loss of RNFL thickness in the peripheral macula in patients with Type 1 DM with no or minimal signs of DR. In the pericentral area of the macula, the RNFL, GCL and IPL were thinner in persons with Type 2 DM and minimal DR compared to controls [32]. Vujosevic et al. [19] demonstrated a significant decrease in RNFL and at specific sites of GCL in the macula in Type 1 and 2 DM patients and no or mild RD. Moreover, Holm et al. [36] described that the nasal area of the macula, where there is a higher density of cones and ganglion cells, was more vulnerable to neurodegenerative processes than the temporal region, showing a lower amplitude and longer implicit time in this specific area with multifocal ERG analysis. In our study, we did not find significant difference in RNFL thickness between the diabetic groups without DR and with NPDR. This is probably due to the fact that all the patients with diabetes were at a very early stage of DR and in fairly good and comparable metabolic control.

In order to analyze the role of glycemic control on neuroretina, we performed a correlation analysis between overall glycemic load, expressed as HbA1c, and GV. It is noteworthy that only GV was associated with abnormalities of specific retinal layers, while no association was observed with HbA1c. In particular, we found a negative correlation between RNFL thickness and LBG1, that represents the frequency and the extent of low blood glucose excursions [18]. In vitro experiments showed a dose-dependent reduction in neuronal survival with decreasing concentrations of glucose in retinal cultures subjected to anoxia. Interestingly, the initial worsening of diabetic retinopathy observed in the early period of intensive glycemic control.
is manifested by the increase in the number of soft exudates, a typical feature of the ischemic retina. These findings indicate that glucose is a fundamental energy substrate in conditions of ischemia and that the ability of the retina to metabolically compensate during periods of low oxygen availability is impaired by low levels of blood glucose, although this is advantageous in terms of delaying the progression of diabetic retinopathy [37]. Therefore, our results confirm the hypothesis that the hyperglycemic excursions may be associated with retinal neurodegeneration [13]. Moreover, we also demonstrate that GV evaluated as CONGA, but not HbA1c, was positively associated with INL thickness, suggesting that an increase in intraday glycemic variation seems to be involved in the development of an early activation of Müller cells. CONGA is unaffected by the asymmetry of a glycemic profile, and it does not require identification of peak or nadirs according to arbitrary definitions, as opposed to the MAGE. Of particular interest, CONGA value under 3 h catches the smaller glycemic swings (that occur over shorter time intervals), and intra-individual CONGA values increased with the time interval with a gradual leveling-off of values after an “n” of 3–4 h [38]. Therefore, our results support the concept that glial activation may be associated both with rapid and small glycemic peaks (expressed by CONGA-1 and- 2), and to the presence of more prolonged and “leveled” blood glucose excursions (CONGA-4). The pathophysiologic mechanism responsible for the association between GV and retinal thickness alterations could be represented by the activation of the oxidative stress pathway induced by GV [39], which is deleterious to the retinal nerve and glial cells [40]. In light of this results, the use of the new long-acting insulins, which are most effective in reducing the GV and hypoglycemia, may represent the best treatment choice in patients with Type 1 DM [41].

Finally, among all metabolic parameters, a positive association between triglycerides and INL thickness was observed. This association is independent of the GV effect on macular thickness. There is significant evidence from two major clinical trials (the FIELD and the ACCORD-Eye studies) [42, 43] that fenofibrate (FA), reducing triglycerides, arrests the progression of DR in Type 2 DM patients. The most accepted hypothesis is related to non-lipid mechanisms of FA. In particular, fenofibric acid exerts a protective effect on the microvasculature by suppressing apoptosis and stimulating endothelial nitric oxide synthase phosphorylation and nitric oxide production, which is mediated by 5’ adenosine monophosphate-activated protein kinase activation. FA, through the PPARα activation, reduces systemic inflammation, inhibits angiogenesis and neovascularization and increases plasma levels of adiponectin in hypertriglyceridemic patients, protecting against retinal vessel injury via modulation of tumor necrosis factor-α inflammatory responses. Finally, FA has protective effects on blood–retinal barrier breakdown [44]. Moreover, in a recent study, treatment with FA in mice with diabetes resulted in a significant decrease in both glial activation and the rate of apoptosis in GL in comparison with mice treated with vehicle [45]. The authors did not associate these findings to the reduction in triglyceride levels. On the other hand, it has been described that apolipoprotein A1 (apo-A1), a key factor for the intraretinal lipids transport and a potent scavenger of reactive oxygen species, is overexpressed in all the neuroretinal layers in persons with diabetes [46]. These findings have led the authors to hypothesize that the higher content of apo-A1 during diabetes was a precocious protective mechanism; consequently, the tardive loss of capacity for apo-A1 production was associated to develop lipid deposition (hard exudates) and retinal damage induced by oxidative stress. To our knowledge, this is the first report showing a direct association between triglycerides levels and very early structural damage of neuroretina in Type 1 DM patients. Further studies are needed to understand the pathogenic mechanisms underlying such relationship.

Neuronal and glial cells interact with vascular cells in the retina forming a neurovascular unit, and Muller cells may represent the “communicator” cell between vessels and neurons [25]. The final balance of the reactive activation of Müller cells induced by glycemic excursions and triglycerides could be on the one hand the breakdown of endothelial cell–cell junctions, on the other hand, earlier, increased loss of retinal nerve fibers [47].

The novelty of our study lies in that the morphological alterations in retinal thickness were observed in a highly selected diabetic population, in good metabolic control and especially not affected by microvascular complications. The main limitations of the present study were related to the small sample size, particularly of the controls. Moreover, CGM was performed only in Type 1 DM group, and therefore, the GV indices were available only for patients with diabetes and not for controls. The lack of follow-up data did not allow to analyze the prognostic role of GV and overall glycemic load on the onset and/or progression in neuroretinal abnormalities.

In conclusion, these results support the concept that glycemic excursions have an early neurodegenerative effect on the retina, which occurs even though the vascular component of DR is minimal. These findings could change our view on DR, traditionally regarded as a microvascular complication of diabetes, suggesting that DR could be a sensory neuropathy that affects the neuroretinal tissue [3]. A suggestive route to take would be to consider retinal neurodegeneration as a predictor of a neuropathic damage extended “beyond the retina” [48]. However, considerable evidence of a potential relationship between retinal neuropathy and peripheral or central nervous system damage is not still completely available.
Acknowledgements The research for this paper was partially financially supported by Italian Ministry of Health and Fondazione Roma.

Author contribution Authorship: F.P., M.P., D.Y. and F.S. researched the data, contributed to the discussion and wrote the manuscript. P.P. contributed to the discussion and wrote the manuscript and S.C., I.G., I.M., P.G., M.V. and D.L. researched the data. S.F. researched the data, contributed to the discussion, wrote the manuscript, reviewed and edited the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standards All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reference

1. Congdon NG, Friedman DS, Liemtan T (2003) Important causes of visual impairment in the world today. JAMA 290:2057–2060
2. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053
3. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 10:124–136. doi:10.1016/S0140-6736(09)62124-3
4. Kaidonis G, Gillies MC, Abhary S et al (2016) A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in caucasian patients. Acta Diabetol 53(4):643–650. doi:10.1007/s00592-016-0850-4
5. Rooney D, Lye WK, Tan G et al (2015) Body mass index and retinopathy in asian populations with diabetes mellitus. Acta Diabetol 52(1):73–80. doi:10.1007/s00592-014-0602-2
6. Lu J, Hou X, Zhang L et al (2015) Association between body mass index and diabetic retinopathy in Chinese patients with type 2 diabetes. Acta Diabetol 52(4):701–708. doi:10.1007/s00592-014-0711-y
7. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R (1997) Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with no-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 96(6):1750–1754
8. Cavalot F, Petrelli A, Traversa M et al (2006) Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91(3):813–819
9. Ceriello A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54(1):1–7
10. Di Flaviani A, Picconi F, Di Stefano P et al (2011) Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 34(7):1605–1609. doi:10.2337/dc11-0034
11. Giordani I, Di Flaviani A, Picconi F et al (2014) Acute hyperglycemia reduces cerebrovascular reactivity: the role of glycemic variability. J Clin Endocrinol Metab 99(8):2854–2860. doi:10.1210/jc.2014-1087
12. Beltram E, Lopatina T, Mazzeo A et al (2016) Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy. Acta Diabetol 53(6):957–964
13. Stem MS, Dunbar GE, Jackson GR, Farsiu S, Pop-Busui R, Gardner TW (2016) Glucose variability and inner retinal sensory neuropathy in persons with type 1 diabetes mellitus. Eye. doi:10.1038/eye.2016.48
14. American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl 1):S64–S71. doi:10.2337/dc12-s064
15. Al Moghtaderi, Bakhshipour A, Rashidi H (2006) Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg 108(5):477–481
16. Ctori I, Huntjens B (2015) Repeatability of foveal measurements using spectralis optical coherence tomography segmentation software. PLoS ONE 10:e0129005
17. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4 The early treatment diabetic retinopathy study research group. Int Ophthalmol Clin 1987; 27:265–272
18. Picconi F, Di Flaviani A, Malandrucco I, Giordani I, Frontoni S (2012) Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin evidence and clinical perspectives. Nutr Metab Cardiovasc Dis 22(9):691–696. doi:10.1016/j.numecd.2012.03.006
19. Vujosevic S, Midena E (2013) Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations. J Diabetes Res 2013:905058. doi:10.1155/2013/905058
20. Scarinci F, Picconi F, Virgili G, Giorno P, Di Renzo A, Varano M, Frontoni S, Parravano M (2016) Single retinal layer evaluation in patients with type 1 diabetes with no or early signs of diabetic retinopathy: the first hint of neurovascular crosstalk damage between neurons and capillaries? Ophthalmologica (in press)
21. Bandello F, Tejerina AN, Vujosevic S (2015) Retinal layer location of increased retinal thickness in eyes with subclinical and clinical macular edema in diabetes type 2. Ophthalmic Res 54(3):112–117. doi:10.1159/000437982
22. van Dijk HW, Kok PH, Garvin M et al (2009) Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 50(7):3404–3409. doi:10.1167/iovs.08-3143
23. Jiang Y, Biswas SK, Steinkel JJ (2014) Serine 307 on insulin receptor substrate 1 is required for SOCS3 and TNF-α signaling in the rMC-1 cell line. Mol Vis 20:1463–1470
24. Simó R, Hernández C (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25:23–33
25. Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E (2015) Aqueous humor biomarkers of Müller cell activation in diabetic eyes. Invest Ophthalmol Vis Sci 56(6):3913–3918. doi:10.1167/iovs.15-16554
26. Li Q, Zemel E, Miller B, Perlman I (2002) Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res 74:615–625
27. Bogdanov P, Corraliza L, Villena JA et al (2014) The db/db mouse: a useful model for the study of diabetic retinal
neurodegeneration. PLoS ONE 9(5):e97302. doi:10.1371/journal.
pone.0097302
28. Matteucci A, Gaddini L, Villa M et al (2014) Neuroprotection by
rat Müller glia against high glucose-induced neurodegeneration
through a mechanism involving ERK1/2 activation. Exp Eye Res
125:20–29. doi:10.1016/j.exer.2014.05.011
29. Bringmann A, Wiedemann P (2012) Müller glial cells in retinal
disease. Ophthalmologica 227(1):1–19. doi:10.1159/00032897
30. Tejerina AN, Vujosevic S, Varano M et al (2015) One-year
progression of diabetic subclinical macular edema in eyes with
mild nonproliferative diabetic retinopathy: location of the
increase in retinal thickness. Ophthalmic Res 54:118–123
31. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P,
Bringmann A (2007) Müller cells as players in retinal degener-
ation and edema. Graefes Arch Clin Exp Ophthalmol
245:627–636
32. van Dijk HW, Verbraak FD, Kok PH et al (2012) Early neu-
rodegeneration in the retina of type 2 diabetic patients. Invest
Ophthalmol Vis Sci 53(6):2715–2719. doi:10.1167/iovs.11-8997
33. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW
(2002) Diabetic retinopathy: more than meets the eye. Surv
Ophthalmol 47(Suppl 2):S253–S262
34. Biallosterski C, van Velthoven ME, Michels RP, Schlingemann
RO, DeVries JH, Verbraak FD (2007) Decreased optical coher-
ence tomography-measured pericentral retinal thickness in
patients with diabetes mellitus type 1 with minimal diabetic
retinopathy. Br J Ophthalmol 91(9):1135–1138
35. van Dijk HW, Verbraak FD, Kok PH et al (2010) Decreased
retinal ganglion cell layer thickness in patients with type 1 dia-
betes. Invest Ophthalmol Vis Sci 51(7):3660–3665. doi:10.1167/
iovs.09-05041
36. Holm K, Lövestam Adrian M (2012) In diabetic eyes, multifocal
ERG reflects differences in function between the nasal part and
the temporal part of the macula. Graefes Arch Clin Exp Oph-
thalmol. 250(8):1143–1148. doi:10.1007/s00417-012-1937-4
37. Casson RJ, Wood JPM, Osborne NN (2004) Hypoglycaemia
exacerbates ischaemic retinal injury in rats. Br J Ophthalmol
88:816–820. doi:10.1136/bjo.2003.024661
38. Cameron FJ, Donath SM, Bagnhurst PA (2010) Measuring gly-
caemic variation. Cur Diabetes Rev 6(1):17–26
39. Monnier L, Mas E, Ginet C et al (2006) Ativation of oxidative
stress by acute glucose fluctuations compared with sustained
chronic hyperglycemia in patients with type 2 diabetes. JAMA
295(14):1681–1687
40. Fletcher EL, Phipps JA, Wilkinson-Berk JL (2005) Dysfunction of
retinal neurons and glia during diabetes. Clin Exp Optom
3:132–145
41. Yamamoto C, Miyoshi H, Fujiwara Y et al (2016) Degludec is
superior to glargine in terms of daily glycemic variability in
people with type 1 diabetes mellitus. Endocr J 63(1):53–60.
doi:10.1507/endocrj.EJ15-0438
42. Keech AC, Mitchell P, Summanen PA, FIELD Study Investiga-
tors et al (2007) Effect of fenofibrate on the need for laser
treatment for diabetic retinopathy (FIELD study): a randomised
controlled trial. Lancet 370:1687–1697
43. ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis
MD, ACCORD Study Group et al (2010) Effects of medical
therapies on retinopathy progression in type 2 diabetes. N Engl J
Med 363:233–244
44. Simó R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY
(2013) Fenofibrate: a New Treatment for Diabetic Retinopathy.
Molecular Mechanisms and Future Perspectives. Curr Med Chem
20:3258–3266
45. Bogdanov P, Hernández C, Corraliza L, Carvalho AR, Simó R
(2015) Effect of fenofibrate on retinal neurodegeneration in an
experimental model of type 2 diabetes. Acta Diabetol
52(1):113–122. doi:10.1007/s00592-014-0610-2
46. Simó R, García-Ramírez M, Higuera M, Hernández C (2009)
Apolipoprotein A1 is overexpressed in the retina of diabetic
patients. Am J Ophthalmol 147(2):319–325. doi:10.1016/j.ajo.
2008.08.009
47. Das A, McGuire PG, Rangasamy S (2015) Diabetic macular
edema: pathophysiology and novel therapeutic targets. Ophthal-
mology 122(7):1375–1394. doi:10.1016/j.ophtha.2015.03.024
48. Selvarajah D, Wilkinson ID, Maxwell M et al (2014) Magnetic
resonance neuroimaging study of brain structural differences in
diabetic peripheral neuropathy. Diabetes Care 37(6):1681–1688.
doi:10.2337/dc13-2610